Ran Frenkel

Insider Reports History

Location
Newton, MA
Signature
/s/ Nancy Smith as Attorney-in-Fact for Ran Frenkel
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Ran Frenkel:

Company Role Class Num Shares Value Price $ Report Date Ownership
Karyopharm Therapeutics Inc. EVP, Chief Dev. Officer Common Stock 168,290 $137,998 $0.8200 28 Feb 2022 Direct
Karyopharm Therapeutics Inc. EVP, Chief Dev. Officer Stock Option (right to buy) 90,000 28 Feb 2022 Direct

Insider Reports Filed by Ran Frenkel

Symbol Company Period Transactions Value $ Form Type Role Filing Time
KPTI Karyopharm Therapeutics Inc. 28 Feb 2022 3 -$17,025 4 EVP, Chief Dev. Officer 02 Mar 2022, 14:34
KPTI Karyopharm Therapeutics Inc. 17 Feb 2022 1 -$35,509 4 EVP, Chief Dev. Officer 22 Feb 2022, 15:16
KPTI Karyopharm Therapeutics Inc. 07 Feb 2022 1 -$19,635 4 EVP, Chief Dev. Officer 09 Feb 2022, 16:26